Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:DNLI NASDAQ:FATE NASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.53-2.5%$2.21$1.09▼$3.40$169.87M0.61741,961 shs263,829 shsDNLIDenali Therapeutics$21.66+3.0%$19.80$12.58▼$23.77$3.44B1.031.80 million shs2.18 million shsFATEFate Therapeutics$2.06+4.6%$1.80$0.91▼$2.88$240.11M2.534.07 million shs4.70 million shsRGNXREGENXBIO$6.66+6.1%$7.98$5.45▼$16.19$344.31M1.041.67 million shs903,377 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%-6.42%-33.48%-30.45%-6.13%DNLIDenali Therapeutics0.00%+10.96%+11.71%+5.30%+42.59%FATEFate Therapeutics0.00%+4.04%+8.42%+76.07%+32.90%RGNXREGENXBIO0.00%+9.54%+6.73%-22.29%-34.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.53-2.5%$2.21$1.09▼$3.40$169.87M0.61741,961 shs263,829 shsDNLIDenali Therapeutics$21.66+3.0%$19.80$12.58▼$23.77$3.44B1.031.80 million shs2.18 million shsFATEFate Therapeutics$2.06+4.6%$1.80$0.91▼$2.88$240.11M2.534.07 million shs4.70 million shsRGNXREGENXBIO$6.66+6.1%$7.98$5.45▼$16.19$344.31M1.041.67 million shs903,377 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%-6.42%-33.48%-30.45%-6.13%DNLIDenali Therapeutics0.00%+10.96%+11.71%+5.30%+42.59%FATEFate Therapeutics0.00%+4.04%+8.42%+76.07%+32.90%RGNXREGENXBIO0.00%+9.54%+6.73%-22.29%-34.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.63136.93% UpsideDNLIDenali Therapeutics 2.87Moderate Buy$34.2558.13% UpsideFATEFate Therapeutics 2.29Hold$5.13148.79% UpsideRGNXREGENXBIO 2.73Moderate Buy$23.55253.54% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, RGNX, FATE, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026RGNXREGENXBIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/8/2026FATEFate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/5/2026RGNXREGENXBIO HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $26.005/22/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $35.005/22/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.005/19/2026FATEFate Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.005/19/2026FATEFate Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/15/2026RGNXREGENXBIO Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.005/15/2026RGNXREGENXBIO BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$37.00 ➝ $12.005/15/2026RGNXREGENXBIO Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $14.005/14/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $40.00(Data available from 6/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$21.05M8.07N/AN/A$0.28 per share5.46DNLIDenali TherapeuticsN/AN/AN/AN/A$6.91 per shareN/AFATEFate Therapeutics$6.32M38.02N/AN/A$1.80 per share1.14RGNXREGENXBIO$87.82M3.92N/AN/A$2.03 per share3.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)DNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)FATEFate Therapeutics-$136.32M-$1.09N/AN/AN/A-2,056.79%-58.89%-39.39%8/11/2026 (Estimated)RGNXREGENXBIO-$193.88M-$5.60N/AN/AN/A-330.23%-232.50%-61.02%8/6/2026 (Estimated)Latest ALEC, RGNX, FATE, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026RGNXREGENXBIO-$1.36-$1.72-$0.36-$1.72$25.84 million$6.39 million5/13/2026Q1 2026FATEFate Therapeutics-$0.29-$0.26+$0.03-$0.26$1.49 million$1.30 million5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.805.255.25DNLIDenali Therapeutics0.019.289.28FATEFate TherapeuticsN/A5.855.85RGNXREGENXBION/A2.622.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%DNLIDenali Therapeutics92.92%FATEFate Therapeutics97.54%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipALECAlector8.30%DNLIDenali Therapeutics12.50%FATEFate Therapeutics4.74%RGNXREGENXBIO14.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million101.81 millionOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableFATEFate Therapeutics550116.56 million111.03 millionOptionableRGNXREGENXBIO37051.70 million44.35 millionOptionableALEC, RGNX, FATE, and DNLI HeadlinesRecent News About These CompaniesWhat is HC Wainwright's Forecast for REGENXBIO Q3 Earnings?June 8, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM)June 6, 2026 | theglobeandmail.comHow The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst CommentaryJune 2, 2026 | finance.yahoo.comREGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 22, 2026 | seekingalpha.comREGENXBIO to Participate in Upcoming Investor ConferencesMay 18, 2026 | prnewswire.comStockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy CandidateMay 18, 2026 | genengnews.comGRegenxbio (RGNX) Q1 2026 Earnings TranscriptMay 18, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS)May 17, 2026 | theglobeandmail.comRegenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD ResultsMay 17, 2026 | seekingalpha.comBank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock PriceMay 15, 2026 | marketbeat.comRegenxbio: Q1 Earnings SnapshotMay 15, 2026 | stamfordadvocate.comSRGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial successMay 15, 2026 | msn.comREGENXBIO Inc. (RGNX) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comRegenxbio's muscle disorder therapy meets main goal in late-stage studyMay 14, 2026 | msn.comRegenxbio slides after late-stage trial data for Duchenne therapyMay 14, 2026 | seekingalpha.comRegenxbio Shares Rise After Positive Duchenne Trial ResultsMay 14, 2026 | finance.yahoo.comRegenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ...May 14, 2026 | finance.yahoo.comREGENXBIO Advances Duchenne Gene Therapy Toward Accelerated ApprovalMay 14, 2026 | benzinga.comRegenxbio (RGNX) Reports Q1 Loss, Lags Revenue EstimatesMay 14, 2026 | zacks.comInsider Selling: REGENXBIO (NASDAQ:RGNX) Insider Sells 15,309 Shares of StockMay 14, 2026 | insidertrades.comREGENXBIO Reports First Quarter 2026 Financial Results and Operational HighlightsMay 14, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, RGNX, FATE, and DNLI Company DescriptionsAlector NASDAQ:ALEC$1.53 -0.04 (-2.55%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.52%) As of 06/12/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Denali Therapeutics NASDAQ:DNLI$21.66 +0.64 (+3.04%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$21.66 0.00 (0.00%) As of 06/12/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Fate Therapeutics NASDAQ:FATE$2.06 +0.09 (+4.57%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.06 0.00 (-0.24%) As of 06/12/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.REGENXBIO NASDAQ:RGNX$6.66 +0.38 (+6.05%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$6.57 -0.09 (-1.35%) As of 06/12/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
